ArticleCurrent drug targets2026
Improving B-cell Linear Epitope Prediction
Article in Current drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
introductionThe identification of linear B-Cell epitopes (BCEs) is significantly important for the discovery of drugs, such as antibody production, peptide-based vaccines, and other therapeutics. MATERIALS AND
methodsUnlike traditional laboratory-based methods, computational techniques can save cost and time in predicting large-scale BCEs. For this purpose, numerous in-silico methods have been designed to enhance the overall efficacy of BCE prediction. However, research gaps exist for further improvement in the context of using novel feature representations and learning models for BCE prediction. Therefore, in the present study, we aimed to design a novel sequence- based predictor named CoBCEs for screening and discriminating accurate BCEs. The proposed CoBCEs model incorporates the notion of graph-based signature, texture-based, and protein language model (pLM)-based features to sufficiently explore the local and global evolutionary information from protein sequences alone. Then, we fed the fused features, i.e., ProtVec sequence embeddings, Distance-Enhanced Graph (DE-Graph), and term frequency-inverse document frequency (TF-IDF), to an ensemble machine learning classifier.
resultsExperimental results of cross-validation and independent tests on several datasets demonstrate that CoBCEs attained superior performance in terms of accuracy, 77.3%, and Matthews correlation coefficient (MCC) of 61.8%, compared with other existing BCE predictors. DISCUSSION: Detailed data analyses show that the major advantage of CoBCEs lies in the combined utilization of graph-based and pLM-based features, which extract more discriminative information from sequences. In the future, we aim to develop a publicly available web server using biological language models for large-scale BCE peptide prediction.
conclusionWe believe our proposed approach will offer valuable insights for drug discovery and disease treatment.
Indexed as
Identifiers
42374910What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.